Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -1.53% to close at $404.12 with the total traded volume of 658631 shares. Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) reported that the U.S. Food and Drug Administration has agreed Dupilumab Biologics License Application or BLA for previousity review. Dupilumab’s BLA is for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis or AD, a serious, chronic inflammatory skin disease.
The application has been given a Prescription Drug User Fee Act or PDUFA target action date of March 29, 2017. The examinational antibody therapy dupilumab inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 (comprising Th2) immune response, which is believed to be a major driver in the pathogenesis of the disease. The firm has institutional ownership of 70.90%, while insider ownership included 0.50%. Its price to sales ratio ended at 9.15. REGN attains analyst recommendation of 2.30 with week performance of 0.32%.
GlobalSCAPE, Inc. (NYSE:GSB) [Trend Analysis] surged reacts as active mover, shares an raise 1.72% to traded at $3.54 and the percentage gap among open changing to regular change was 0.57%. GlobalSCAPE, Inc. (NYSE MKT:GSB) has been selected for CRN’s 2016 Cloud Computing Partner Program Guide, a list of leading technology vendors with cloud-related partner programs that enable and accelerate the growth of solution providers’ cloud initiatives.
Tamela Gates May, Vice President of Channel Sales and Marketing at Globalscape; “Globalscape’s channel program is a component of the firm’s growth strategy and our global network of channel partners are indispensable to our continued success. Inclusion in CRN’s Cloud Partner Program Guide is additional proof of Globalscape’s continuing innovation in cloud solutions, as well as of our commitment to provide our channel partners with products and support that help them meet their consumers’ business needs.”
The firm’s current ratio calculated as 2.00 for the most recent quarter. The firm past twelve months price to sales ratio was 2.36 and price to cash ratio remained 3.69. As far as the returns are concern, the return on equity was recorded as 14.70% and return on investment was 17.60% while its return on asset stayed at 8.70%. The firm has total debt to equity ratio measured as 0.00.
Concordia International Corp. (NASDAQ:CXRX) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -6.57% to $4.98. The share price of CXRX attracts active investors, as stock price of week volatility recorded 11.73%. The stock is going forward to its 52-week low with 11.91% and lagging behind from its 52-week high price with -92.59%.